Project Grant R21HL177481
- This federal Project Grant award of $621,546.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), focuses on observing the single molecule dynamics of the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) under both normal and disease-associated conditions. The primary objectives are to: 1) Engineer a single-walled carbon nanotube field effect transistor (SWNT FET) system to record PKA-C single molecule...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $580,863 to Clemson University starting on Dec 23, 2024 to develop engineered human cardiac organoids for heart repair. The project aims to optimize the design of electrically conductive silicon nanowires within the organoids and use pharmacological preconditioning to improve cell survival after implantation. Two sub-awards totaling an unspecified...
- This $556,295 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance scientific understanding of cardiac pacemaking and sinus node dysfunction (SND) through research on "conditional pacemaker cells" within distinct specialized pacemaker cell subpopulations. The project will leverage advanced optical mapping technology to directly visualize pacemaking activities within these specialized cell...
- The federal Project Grant award of $507,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop an automated system that integrates micro-electromechanical sensors, automation, and machine vision to simultaneously measure electrophysiological properties and contractile forces in single human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). This innovative system is expected to significantly reduce measurement time...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research on how tissue elasticity and viscosity modulate the signaling between macrophages and fibroblasts in cardiac fibrosis. The $231,552 award, granted to the University of California, San Diego, will fund research to investigate the effects of mechanical stimuli on macrophage-fibroblast interactions and explore the role of a changing mechanical...
- This Project Grant award, valued at $498,991.40, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas, Fayetteville. The goal is to engineer microphysiological systems with tight oxygen control to investigate the molecular pathways activated in oxygen gradients and the resulting effects on cardiomyocyte function, in order to obtain a comprehensive understanding of the cardiac response to hypoxic...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- This federal Project Grant award, valued at $765,288.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research at the University of California, San Diego (UCSD) to investigate the biological mechanisms of the infarct borderzone - the complex and dynamic region between areas of cell death and normal tissue in the heart following a myocardial infarction. The research aims to advance...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research to develop a biomolecular-based technology that can locally deliver photocurrents to cardiomyocytes. The $350,112 project, running from August 1, 2025 to July 31, 2027, aims to create free-standing nanostructures that are photocurrent-generating and cell-interacting, serving as phototransducer cardiac biomaterials. The research being conducted at the University of California, Irvine is focused on using complementary peptide pairs to organize energy transporting organic donor-acceptor units in a sequence-controllable manner, with the goal of producing materials that can stimulate cardiac cells with high spatiotemporal resolution through photoinduced processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $350.1k | 7/30/25 |